Tocilizumab, a humanized anti-IL6R monoclonal antibody approved for rheumatoid arthritis, disturbs both classical and trans-signaling and improved the symptoms in a patient with mixed connective tissue disease and severe refractory PAH [54]. The gene discussed is IL6R; the disease is pulmonary arterial hypertension.